Cite
Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens
MLA
Beelen, Dietrich, et al. “Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens.” Biology of Blood & Marrow Transplantation, vol. 25, no. 3, Mar. 2019, p. S3. EBSCOhost, https://doi.org/10.1016/j.bbmt.2018.12.685.
APA
Beelen, D., Markiewicz, M., Stelljes, M., Remenyi, P., Wagner-Drouet, E.-M., Dreger, P., Bethge, W., Ciceri, F., Stölzel, F., Junghanß, C., Michallet, M., Schaefer-Eckart, K., Grigoleit, G., Scheid, C., Patriarca, F., Mico, M. C., Niederwieser, D., Hilgendorf, I., Russo, D., & Socié, G. (2019). Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens. Biology of Blood & Marrow Transplantation, 25(3), S3. https://doi.org/10.1016/j.bbmt.2018.12.685
Chicago
Beelen, Dietrich, Miroslaw Markiewicz, Matthias Stelljes, Peter Remenyi, Eva-Maria Wagner-Drouet, Peter Dreger, Wolfgang Bethge, et al. 2019. “Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens.” Biology of Blood & Marrow Transplantation 25 (3): S3. doi:10.1016/j.bbmt.2018.12.685.